Rigel Pharmaceuticals, Inc.
Symbol: RIGL
NASDAQ
1.1
USDMarktpreis heute
-7.4054
P/E-Verhältnis
3.7767
PEG-Verhältnis
192.92M
MRK Kapital
- 0.00%
DIV Rendite
Rigel Pharmaceuticals, Inc. (RIGL) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 242.3 | 56.9 | 58.2 | 125 | |||||||||||||||||||||||||
balance-sheet.row.short-term-investments | 75.01 | 24.1 | 33.7 | 106.1 | |||||||||||||||||||||||||
balance-sheet.row.net-receivables | 104.28 | 30.6 | 40.3 | 15.5 | |||||||||||||||||||||||||
balance-sheet.row.inventory | 33.49 | 5.5 | 9.1 | 6.6 | |||||||||||||||||||||||||
balance-sheet.row.other-current-assets | 22.11 | 6.3 | 8.3 | 7.4 | |||||||||||||||||||||||||
balance-sheet.row.total-current-assets | 402.19 | 99.3 | 115.9 | 154.5 | |||||||||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 4.85 | 1 | 2.8 | 11.9 | |||||||||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
balance-sheet.row.intangible-assets | 57.12 | 13.9 | 14.9 | 0 | |||||||||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 57.12 | 13.9 | 14.9 | 0 | |||||||||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
balance-sheet.row.other-non-current-assets | 9.09 | 3.1 | 0.6 | 1 | |||||||||||||||||||||||||
balance-sheet.row.total-non-current-assets | 71.06 | 18 | 18.4 | 12.9 | |||||||||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
balance-sheet.row.total-assets | 473.25 | 117.2 | 134.3 | 167.3 | |||||||||||||||||||||||||
balance-sheet.row.account-payables | 26.68 | 7.1 | 22.5 | 3.8 | |||||||||||||||||||||||||
balance-sheet.row.short-term-debt | 9.51 | 7.9 | 1.1 | 9.9 | |||||||||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
balance-sheet.row.long-term-debt-total | 233.27 | 52.7 | 40.4 | 20.7 | |||||||||||||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||||||||||
balance-sheet.row.other-current-liab | 119.69 | 21.2 | 28.1 | 47.3 | |||||||||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 395.02 | 92.6 | 82.7 | 73.4 | |||||||||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 4.46 | 1 | 2.1 | 10.7 | |||||||||||||||||||||||||
balance-sheet.row.total-liab | 586.1 | 145.9 | 147.9 | 137 | |||||||||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
balance-sheet.row.common-stock | 0.7 | 0.2 | 0.2 | 0.2 | |||||||||||||||||||||||||
balance-sheet.row.retained-earnings | -5614.43 | -1407.5 | -1382.5 | -1323.9 | |||||||||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.06 | 0 | -0.2 | -0.1 | |||||||||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 5500.94 | 1378.7 | 1368.8 | 1354.2 | |||||||||||||||||||||||||
balance-sheet.row.total-stockholders-equity | -112.85 | -28.6 | -13.6 | 30.4 | |||||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 473.25 | 117.2 | 134.3 | 167.3 | |||||||||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
balance-sheet.row.total-equity | -112.85 | -28.6 | -13.6 | 30.4 | |||||||||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 473.25 | - | - | - | |||||||||||||||||||||||||
Total Investments | 75.01 | 24.1 | 33.7 | 106.1 | |||||||||||||||||||||||||
balance-sheet.row.total-debt | 242.78 | 60.6 | 41.6 | 30.6 | |||||||||||||||||||||||||
balance-sheet.row.net-debt | 75.48 | 27.8 | 17.1 | 11.7 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -25.09 | -25.1 | -58.6 | -17.9 | |||||||||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 1.24 | 1.2 | 1 | 1.2 | |||||||||||||||||||||||||
cash-flows.row.deferred-income-tax | 3.99 | -10.6 | 0 | 0.3 | |||||||||||||||||||||||||
cash-flows.row.stock-based-compensation | 8.81 | 8.8 | 12.4 | 9.5 | |||||||||||||||||||||||||
cash-flows.row.change-in-working-capital | 9.52 | 9.5 | -29 | 9.7 | |||||||||||||||||||||||||
cash-flows.row.account-receivables | 9.77 | 9.8 | -24.8 | 0.5 | |||||||||||||||||||||||||
cash-flows.row.inventory | 1.17 | 1.2 | -2.4 | -4.9 | |||||||||||||||||||||||||
cash-flows.row.account-payables | -0.37 | -0.4 | 3.8 | 0 | |||||||||||||||||||||||||
cash-flows.row.other-working-capital | -1.06 | -1.1 | -5.6 | 14.1 | |||||||||||||||||||||||||
cash-flows.row.other-non-cash-items | -4.21 | 10.4 | 0.5 | 3.1 | |||||||||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -5.74 | 0 | 0 | 0 | |||||||||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -15.13 | -15 | -0.5 | -0.6 | |||||||||||||||||||||||||
cash-flows.row.acquisitions-net | 0.26 | 0.3 | 0.9 | 0.6 | |||||||||||||||||||||||||
cash-flows.row.purchases-of-investments | -31.33 | -31.2 | -28.9 | -141.5 | |||||||||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 41.65 | 41.6 | 101.2 | 62 | |||||||||||||||||||||||||
cash-flows.row.other-investing-activites | 3.23 | 0 | 0 | -0.6 | |||||||||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -4.3 | -4.3 | 72.8 | -80 | |||||||||||||||||||||||||
cash-flows.row.debt-repayment | -20.93 | -17.3 | -4.4 | -57.9 | |||||||||||||||||||||||||
cash-flows.row.common-stock-issued | 1.05 | 1 | 2.1 | 4.8 | |||||||||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
cash-flows.row.other-financing-activites | 36.93 | 34.6 | 8.9 | 115.8 | |||||||||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 18.37 | 18.4 | 6.5 | 62.7 | |||||||||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -1.01 | 0 | 0 | 0 | |||||||||||||||||||||||||
cash-flows.row.net-change-in-cash | 8.33 | 8.3 | 5.6 | -11.5 | |||||||||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 167.3 | 32.8 | 24.5 | 18.9 | |||||||||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 158.97 | 24.5 | 18.9 | 30.4 | |||||||||||||||||||||||||
cash-flows.row.operating-cash-flow | -5.74 | -5.7 | -73.8 | 5.9 | |||||||||||||||||||||||||
cash-flows.row.capital-expenditure | -15.13 | -15 | -0.5 | -0.6 | |||||||||||||||||||||||||
cash-flows.row.free-cash-flow | -20.88 | -20.7 | -74.2 | 5.3 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 116.88 | 116.9 | 120.2 | 149.2 | |||||||||||||||||||||||||
income-statement-row.row.cost-of-revenue | 7.11 | 7.1 | 1.7 | 1.1 | |||||||||||||||||||||||||
income-statement-row.row.gross-profit | 109.77 | 109.8 | 118.5 | 148.2 | |||||||||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||||||||
income-statement-row.row.research-development | 24.52 | - | - | - | |||||||||||||||||||||||||
income-statement-row.row.selling-general-administrative | 26.31 | - | - | - | |||||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 1.3 | 3.5 | |||||||||||||||||||||||||
income-statement-row.row.operating-expenses | 130.26 | 130.3 | 172.7 | 157.1 | |||||||||||||||||||||||||
income-statement-row.row.cost-and-expenses | 137.37 | 137.4 | 174.5 | 158.2 | |||||||||||||||||||||||||
income-statement-row.row.interest-income | 2.27 | 2.3 | 0.7 | 0 | |||||||||||||||||||||||||
income-statement-row.row.interest-expense | 6.87 | 6.9 | 3.7 | 4.9 | |||||||||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -4.6 | -4.6 | -4.3 | -8.3 | |||||||||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 1.3 | 3.5 | |||||||||||||||||||||||||
income-statement-row.row.total-operating-expenses | -4.6 | -4.6 | -4.3 | -8.3 | |||||||||||||||||||||||||
income-statement-row.row.interest-expense | 6.87 | 6.9 | 3.7 | 4.9 | |||||||||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 1.63 | 1.2 | 0.7 | 0 | |||||||||||||||||||||||||
income-statement-row.row.ebitda-caps | -17.28 | - | - | - | |||||||||||||||||||||||||
income-statement-row.row.operating-income | -20.49 | -20.5 | -54.2 | -9 | |||||||||||||||||||||||||
income-statement-row.row.income-before-tax | -25.09 | -25.1 | -58.6 | -17.3 | |||||||||||||||||||||||||
income-statement-row.row.income-tax-expense | 2.39 | 2.3 | 3 | 0.6 | |||||||||||||||||||||||||
income-statement-row.row.net-income | -25.9 | -25.1 | -61.6 | -17.9 |
Häufig gestellte Frage
Wie hoch ist die Rigel Pharmaceuticals, Inc. (RIGL) Gesamtvermögen?
Rigel Pharmaceuticals, Inc. (RIGL) Gesamtvermögen ist 117225000.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 63926000.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.939.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist -0.120.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist -0.222.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist -0.175.
Was ist der Rigel Pharmaceuticals, Inc. (RIGL) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist -25091000.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 60579000.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 130263000.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 32786000.000.